Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-1
- Development stage
- Preclinical
- Lead developer
- Shanghai KeChow Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MT-1 is an investigational drug candidate being developed by KeChow Pharma. According to the company's research and development pipeline, it is currently in development with a projected timeline reaching into 2026. While specific details regarding its molecular target and mechanism of action are not publicly disclosed in the available pipeline summaries, KeChow Pharma primarily focuses on small molecule therapeutics for oncology, particularly targeting the MAPK pathway (including MEK and BRAF inhibitors) and other tumor-related pathways such as KRAS and pan-RAF. MT-1 is listed as a distinct program in their pipeline, separate from their lead MEK inhibitor tunlametinib (HL-085).
Beyond the preview
Go deeper on MT-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-1.